DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) (USD $)	12 Months Ended					12 Months Ended			12 Months Ended					12 Months Ended		12 Months Ended
	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012	Mar. 29, 2014 Credit Agreement	Dec. 29, 2012 Credit Agreement	Mar. 29, 2014 Foreign Exchange Contract	Mar. 29, 2014 Designated as Hedging Instrument Foreign Exchange Contract	Mar. 30, 2013 Designated as Hedging Instrument Foreign Exchange Contract	Mar. 29, 2014 Designated as Hedging Instrument Interest Rate Swap	Mar. 29, 2014 Designated as Hedging Instrument Cash Flow Hedging	Mar. 30, 2013 Designated as Hedging Instrument Cash Flow Hedging	Mar. 31, 2012 Designated as Hedging Instrument Cash Flow Hedging	Dec. 29, 2012 Designated as Hedging Instrument Interest Rate Swap	Mar. 29, 2014 Not Designated as Hedging Instrument Foreign Exchange Contract	Mar. 30, 2013 Not Designated as Hedging Instrument Foreign Exchange Contract	Mar. 29, 2014 Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] Designated as Hedging Instrument Foreign Exchange Contract	Mar. 30, 2013 Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] Designated as Hedging Instrument Foreign Exchange Contract	Mar. 31, 2012 Net Revenues Cost Of Goods Sold And Selling General And Administrative Expense [Member] Designated as Hedging Instrument Foreign Exchange Contract	Mar. 29, 2014 Other income (expense), net Designated as Hedging Instrument Interest Rate Swap	Mar. 30, 2013 Other income (expense), net Designated as Hedging Instrument Interest Rate Swap	Mar. 29, 2014 Hemerus Medical, LLC [Member] FDA Approval of SOLX [Member]	Mar. 30, 2013 Hemerus Medical, LLC [Member] FDA Approval of SOLX [Member]	Mar. 29, 2014 Hemerus Medical, LLC [Member] FDA Approval of SOLX [Member] Fair Value Adjustment
Derivative [Line Items]
Adjusted libor rounding percentage					0.625%
Percentage of sales generated outside the US						46.60%
Maturity period for foreign currency contracts (in years)						1 year
Designated foreign currency hedge contracts outstanding							$ 157,900,000	$ 133,300,000
Gain (loss) on cash flow hedge in earnings										8,600,000	2,700,000	(3,200,000)
Amount of Loss Recognized in OCI (Effective Portion)														0		3,712,000	5,104,000	3,140,000	1,289,000	800,000
Deferred tax benefit	(202,000)	589,000	5,878,000				(100,000)		(500,000)
Non-designated foreign currency hedge contracts outstanding														72,900,000	65,600,000
Long-term debt	440,287,000
Variable rate basis	LIBOR			1-month USD-LIBOR-BBA
Contingent consideration income	(45,000)	0	2,154,000
Derivative, Fixed Interest Rate													0.68%
Derivative, Notional Amount													250,000,000
Contingent consideration amount owed																					$ 7,645,000	$ 7,600,000	$ 45,000